Montek S. Boparai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Montek S. Boparai has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Timothy Q. Duong
Department of Radiology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, USA
2 shared publications Benjamin Musheyev
Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, United States
1 shared publicationJacob Gordon
Renaissance School of Medicine at Stony, Brook University, Stony Brook, USA
1 shared publicationMark F. Mehler
Department of Neurology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, NY, United States
1 shared publicationRyan Lee
Renaissance School of Medicine at Stony, Brook University, Stony Brook, USA
1 shared publicationSandi Bajrami
Renaissance School of Medicine at Stony, Brook University, Stony Brook, USA
1 shared publication
Latest Publications
- Open Access
- 6 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Incidence and risk factors of new-onset hypertension up to 3 years post SARS-CoV-2 infection
COVID-19 can trigger new cardiovascular events, including hypertension, in the acute setting. However, few studies have reported sustained new-onset hypertension post-infection. Moreover, these studies have a small sample size, inadequate controls, and a short (< 1 year) follow-up time. This retrospective cohort study of 64,000 COVID-19 patients) from the Stony Brook Health System assessed the incidence and risk factors for new-onset hypertension after COVID-19. Contemporary COVID-negative controls were obtained and propensity-matched for age, race, sex, ethnicity, and major comorbidities before analyzing outcomes. The primary outcome was new-onset hypertension up to 3 years post-index date. About 9.93% of hospitalized patients and 4.66% of non-hospitalized patients developed new-onset hypertension after COVID-19. Hospitalized COVID-positive patients were more likely to develop hypertension compared to COVID-negative controls (Hazard Ratio [HR] = 1.57, 95% Confidence Interval [CI] [1.35–1.81]) and non-hospitalized COVID-positive controls (HR: 1.42, 95%CI [1.24–1.63]). Non-hospitalized COVID-positive patients were not more likely to develop hypertension than COVID-negative controls (HR: 1.05, 95%CI [0.98–1.13]). COVID-19 was one of the five greatest risk factors for developing hypertension. COVID-19 patients are at increased risk of developing hypertension beyond the acute phase of the disease compared to controls. Long-term follow-up, holistic workups, and vigilant blood pressure screening and/or monitoring for COVID-19 patients are needed.
- 6 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Open AccessIncidence and risk factors of new-onset hypertension up to 3 years post SARS-CoV-2 infection
COVID-19 can trigger new cardiovascular events, including hypertension, in the acute setting. However, few studies have reported sustained new-onset hypertension post-infection. Moreover, these studies have a small sample size, inadequate controls, and a short (< 1 year) follow-up time. This retrospective cohort study of 64,000 COVID-19 patients) from the Stony Brook Health System assessed the incidence and risk factors for new-onset hypertension after COVID-19. Contemporary COVID-negative controls were obtained and propensity-matched for age, race, sex, ethnicity, and major comorbidities before analyzing outcomes. The primary outcome was new-onset hypertension up to 3 years post-index date. About 9.93% of hospitalized patients and 4.66% of non-hospitalized patients developed new-onset hypertension after COVID-19. Hospitalized COVID-positive patients were more likely to develop hypertension compared to COVID-negative controls (Hazard Ratio [HR] = 1.57, 95% Confidence Interval [CI] [1.35–1.81]) and non-hospitalized COVID-positive controls (HR: 1.42, 95%CI [1.24–1.63]). Non-hospitalized COVID-positive patients were not more likely to develop hypertension than COVID-negative controls (HR: 1.05, 95%CI [0.98–1.13]). COVID-19 was one of the five greatest risk factors for developing hypertension. COVID-19 patients are at increased risk of developing hypertension beyond the acute phase of the disease compared to controls. Long-term follow-up, holistic workups, and vigilant blood pressure screening and/or monitoring for COVID-19 patients are needed.
- Open Access
- 12 October 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1258352
Brain MRI findings in severe COVID-19 patients: a meta-analysis
Introduction: Neurocognitive symptoms and dysfunction of various severities have become increasingly recognized as potential consequences of SARS-CoV-2 infection. Although there are numerous observational and subjective survey-reporting studies of neurological symptoms, by contrast, those studies describing imaging abnormalities are fewer in number.Methods: This study conducted a metanalysis of 32 studies to determine the incidence of the common neurological abnormalities using magnetic resonance imaging (MRI) in patients with COVID-19.Results: We also present the common clinical findings associated with MRI abnormalities. We report the incidence of any MRI abnormality to be 55% in COVID-19 patients with perfusion abnormalities (53%) and SWI abnormalities (44%) being the most commonly reported injuries. Cognitive impairment, ICU admission and/or mechanical ventilation status, older age, and hospitalization or longer length of hospital stay were the most common clinical findings associated with brain injury in COVID-19 patients.Discussion: Overall, the presentation of brain injury in this study was diverse with no substantial pattern of injury emerging, yet most injuries appear to be of vascular origin. Moreover, analysis of the association between MRI abnormalities and clinical findings suggests that there are likely many mechanisms, both direct and indirect, by which brain injury occurs in COVID-19 patients.
- 12 October 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1258352
Open AccessBrain MRI findings in severe COVID-19 patients: a meta-analysis
Introduction: Neurocognitive symptoms and dysfunction of various severities have become increasingly recognized as potential consequences of SARS-CoV-2 infection. Although there are numerous observational and subjective survey-reporting studies of neurological symptoms, by contrast, those studies describing imaging abnormalities are fewer in number.Methods: This study conducted a metanalysis of 32 studies to determine the incidence of the common neurological abnormalities using magnetic resonance imaging (MRI) in patients with COVID-19.Results: We also present the common clinical findings associated with MRI abnormalities. We report the incidence of any MRI abnormality to be 55% in COVID-19 patients with perfusion abnormalities (53%) and SWI abnormalities (44%) being the most commonly reported injuries. Cognitive impairment, ICU admission and/or mechanical ventilation status, older age, and hospitalization or longer length of hospital stay were the most common clinical findings associated with brain injury in COVID-19 patients.Discussion: Overall, the presentation of brain injury in this study was diverse with no substantial pattern of injury emerging, yet most injuries appear to be of vascular origin. Moreover, analysis of the association between MRI abnormalities and clinical findings suggests that there are likely many mechanisms, both direct and indirect, by which brain injury occurs in COVID-19 patients.